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In conclusion I would like to stress the importance of histological confirmation of the clinical diagnosis in all cases of thyroid enlargement. This is especially relevant in cases of nodular colloid goitre which present clinically with a solitary thyroid nodule as one of the nodules may prove to be carcinomatous. A recent case, occurring in a 20-year-old woman, illustrates this point. This patient was found to have a small palpable nodule in the thyroid gland which appeared clinically benign. At operation this nodule was found to be a papillary carcinoma but the remainder of the gland was slightly enlarged and lobulated. Histological examination of the thyroidectomy specimen revealed multiple foci of papillary adenocarcinoma throughout one lobe of the gland and the whole thyroid was pale and lobulated due to a diffuse lymphadenoid goitre. Without histological examination, therefore, diagnostic accuracy is impossible. (Halnan 1963 ). This paper considers briefly some details of treatment, dealing in turn with X-ray therapy, hormones and radioactive iodine. X-ray Therapy X-ray therapy is by no-means outmoded. One can be reasonably certain of the dose being given and only a localized volume of tissue is necessarily being treated. There are difficulties because of the anatomy of the thyroid gland. The lower pole of one or both lobes is often almost within the chest and treatment confined to the neck must often be inadequate. A transverse anatomical section ( Fig  1) makes this clear, and draws attention to the considerable variation in the contours of the body corresponding to the upper and lower poles of the gland, varying from the approximately circular and relatively small neck, to the large section through the upper chest and shoulders. One is also reminded that the vertebra and spinal cord are nearer the centre rather than the back, and that much of the posterior half of the neck and upper chest is occupied by muscle and other irrelevant tissue.
The pathology of thyroid cancer is highly important. Detailed examination of total thyroidectomy specimens shows that even well-differentiated papillary or follicular carcinomas are very commonly multifocal (Clark et al. 1959 , Black et al. 1960 . Apart from confirming that total thyroidectomy is usually the surgical operation of choice, this also emphasizes the necessity of treating both sides of the neck or of giving radioiodine if only partial thyroidectomy has been performed. Local spread of the primary tumour is, of course, to the trachea and thyroid and cricoid cartilages, into the soft tissues of the neck and alongside the trachea down into the mediastinum. Lymph-node metastasis to upper, middle and lower deep cervical, and to supraclavicular nodes, is well known, but metastasis is also common in the central delphian nodes and in the chain of paratracheal lymph nodes. Although there is commonly mediastinal metastasis, there is only rarely involvement of the occipital nodes and never, in the author's experience, of pre-auricular nodes.
The radiosensitivity of the normal thyroid is low. Hypothyroidism is uncommon after X-ray therapy alone; one exceptional case at Manchester, without evidence either of thyrotoxicosis or of functioning metastases, was still not hypothyroid after, successively, a three-quarter thyroidectomy, radical X-ray therapy, and 60 mc iodine 131. For partial thyroid ablation for cardiac disease 25 mc iodine 131 is usually needed; for complete ablation 75-100 mc is advisable, and the sudden discharge of radioiodine occurs two to five days after the dose, i.e. after a radiation dose of, say, 40,000 rads. When considering adenocarcinoma in general one knows that apparent radiosensitivity is not high, but that undifferentiated cancer may appear less radio-resistant. This is probably true with thyroid cancer (Windeyer 1954) . The long survival of some cases of papillary cancer may have misled some observers into the belief that it is more sensitive than other differentiated adenocarcinomata. In practice normal tissue tolerance is usually the limiting factor, particularly when considering the volume that needs treatment, sometimes including the spinal cord and almost always the larynx and trachea. Analysis of survival in relation to radiation dose given by radical X-ray therapy is shown in Table 1 . The most common comparable group of cases is that in which there is inoperable cancer confined to the neck, and in which a full course of treatment is practicable and justifiable. During the period considered, 1945-55, radical treatment was usually given over three weeks with a nominal tumour dosage of 2,500-4,000 roentgens. It is convenient to divide them into those given 3,250 r or more, and those given 3,000 r or less. If these results suggest anything it is that volume is more important than high dosage in undifferentiated cases, whereas in differentiated cancer there seems little significant difference. It may be that few of these treatments were at high enough dosage. When discussing treatment one can classify patients into four stages: (1) Operable. (2) Inoperable but confined to the neck. (3) With spread to the mediastinum. (4) With distant metastases.
In stage 1, where radical operation has been apparently successful, it does not seem worth while giving any immediate post-operative X-ray therapy if the tumour is well differentiated, although if total thyroidectomy has not been done, or is impracticable, radioiodine treatment should be given. If the tumour is undifferentiated local recurrence is very likely, and X-ray therapy seems always necessary. All stage 2 cases will need X-ray therapy. One will usually need to treat the whole of the anterior half of the neck, usually with a small part of the upper mediastinum. Using megavoltage X-rays with wedge filters, two useful methods can be planned (Halnan & Paterson 1963 ). The first is simple, two opposing fields, anterior to the spinal cord, angled down into the mediastinum, with wedge filters to compensate for the angulation. A second method is to employ a single plane anterior field with two lateral oblique wedged fields from the front, again avoiding the cord. The considerable anatomical variation from neck to chest necessitates compensation by considerable quantities of wax or bolus, or vertical wedges too. Dosage will depend upon length of field mainly, but will be something of the order of 4,000-5,000 rads in three weeks, to 4,500 -5,000 in five weeks for field lengths of perhaps 8 to 15 cm.
When stage 3 is reached regional treatment only is possible, and a parallel anterior and posterior pair of fields can include the neck and appropriate part of the mediastinum, equivalent to the trunk bridge method using medium voltage X-rays. This treatment can occasionally be curative, probably when the tumour is really of the malignant lymphoreticular type, even though this may not have been obvious from the histology. Treatment dosage can now be the usual 2,500-3,500 rads in three weeks, or 3,000-4,000 rads in five weeks. When there are distant metastases it is still often useful to give treatment to the primary tumour to relieve dyspnoea from tracheal compression, or dysphagia. Painful bone metastases and other deposits causing trouble can, of course, very usefully be treated, from something like 1,500 rads in a single exposure to 2,500 rads over eight days.
Hormones
Administration of thyroid hormone is not only of benefit to relieve hypothyroidism, but can occasionally cause regression of well-differentiated thyroid cancer. It is obvious that the thyroid is thyrotrophin dependent when one considers, for example, Sheehan's disease or panhypopituitarism. In this disease the pituitary thyrotrophic hormone secretion fails completely, and consequently the thyroid slowly atrophies, the patient often becoming almost fully myxcedematous.
There are now many recorded cases of a similar regression of thyroid cancer after hormone treatment to suppress thyrotrophin secretion (Crile 1957 , Thomas & Burns 1961 . This is, of course, the basis of the thyroxine suppression test for thyrotoxicosiswhen one gives a normal patient thyroid hormone the radioiodine uptake of his thyroid gradually decreases (whereas the autonomous toxic thyroid is not affected). Thyroid hormone should, therefore, be given to all patients with thyroid cancer.
Three forms can be used. Dried thyroid is the cheapest, but should not be used since its potency is variable, probably because of deterioration after storage. Sodium L-thyroxine is probably the best; an average adult dose is 0-3 mg daily, but 0-2 mg may be all some women can take, whilst some patients may need as much as 0 5 mg. Sodium L-tri-iodothyronine is quicker acting and this can be useful as well as because its effect also wears off more quickly than that of thyroxine (Halnan & Pochin 1958) ; 120 pg of tri-iodothyronine appears about equal in effect to 0-3 mg of thyroxine. Except in patients being given intermittent hormone treatment because of radioiodine treatment, thyroxine seems better because daily administration is adequate, without the need to split up doses throughout the day. When giving radioiodine tests or treatment it is essential to stop thyroxine administration four weeks previously, and to discontinue tri-iodothyronine two weeks before radioiodine. Administration of either form can be resumed forty-eight hours after radioiodine.
Thyrotrophic hormone is effective within twenty-four hours. Its effect wears off equally quickly and several daily injections of 10 i.u. are advisable if one is trying to stimulate thyroid cancer.
Radioactive Iodine
When treatment by radioiodine is to be used ablation of the normal thyroid is an essential first step. Positive evidence of tumour uptake before ablation is encouraging, but negative evidence should not dissuade one from continuing with thyroid ablation. What is essential is good histological evidence of the nature of the cancer. A true undifferentiated tumour will only rarely concentrate. The follicular variety of differentiated cancer may be best for uptake, but other differentiated varieties may also concentrate iodine, including not only apparently pure papillary cancer, but also Hurthle cell, hypernephromatoid and 'solid' tumours. The reason for this may be, as is often seen at post-mortem, that there is considerable variation of histology between primary and metastases, and between different parts of a large tumour. In tissue culture the histology can also be seen to change (Dobyns & Lennon 1952) .
First, 75-100 mc of iodine 131 will be needed for thyroid ablation, and then one must await hypothyroidism for six to eight weeks. After this time further radioiodine tests should be done. One then needs some criterion on which to decide whether it is worth giving a treatment dose. Concentration of radioiodine is the important factor, rather than total uptake (Halnan 1959) . A normal thyroid concentrates about 1-2%/4/g (25-50% in 25 g). At this level P radiation would be 31,000 -62,000 rads per 100 mc iodine 131, with an average biological half life of three daysas is common in carcinoma (Table 2) . At a concentration of 0p 1 %/g the radiation dosage will still be substantial, 3,100 rads per 100 mc, and this concentration is probably about the lowest worth considering. It should be remembered that, with this concentration, a patient with minimal residual post-operative tumour, say 5 g, will only have a 0.5 % uptake; and conversely a patient with considerable and large metastases, say 250 g, will have a 25 % uptake. Gamma dosage from iodine 131 is only small and not worth considering unless the tumour is large (Table 3) . The maximum safe dose of radioiodine will need to be given. One approach (Paterson et al. 1952 ) is to calculate whole body radiation. This is not at all difficult if done simply by using two daily measurementsuptake in tumour and excretion in urine. One can then first calculate whole body radiation from radioiodine in tumour. The next step is to assume that all radioiodine not accounted for in either tumour or urine is distributed uniformly throughout the body and calculate, whole body dosage accordingly. An alternative is to measure plasma radioiodine and to calculate radiation from this (Table 4) ; plasma radiation does not seem greatly different from whole body radiation and this calculation is not nullified by loss of urine. One then knows the quantity of iodine 131, usually 200-400 mc, that will give a safe maximum whole body radiation of 200 rads (Benau et al. 162y The only disadvantage of this method is that the treatment dose will often be excreted more quickly than the test dose, the whole body dose will be less, and one could have given a larger quantity (Fig 2A) . The second method (Hilton et al. 1956 ) is to decide, arbitrarily but from considerable experience, that 150 mc is a safe maximal repeatable dose, and give this dose at intervals of two to three months until uptake is too low to give any further. A considerable total time is involved, since up to about six doses may be given without harm, if needed ( Fig 2B) . A third method, used at Manchester in 7 patients, is to give a fractionated maximal dose, giving a substantial dose twice weekly until either uptake is abolished, or the patient's white cell count has fallen to, say, an arbitrary 3,000 per c.mm (Fig 2c) . The difficulties encountered are not only that the total safe quantity is too low, but also that the concentration is patchy and not homogeneous, and probably continuously variable. The fractionated method does at least have the possibility of attaining a higher biological radiation dose in the tumour, like fractionated X-ray therapy. The necessary proviso that the tumour retains ability to concentrate iodine holds for a time (perhaps the usual radiation latent period) and one can observe uptake gradually falling as successive doses are given. A further possible advantage is that the patient is necessarily not taking thyroxine for the whole period, and therefore the tumour is under continuous thyrotrophic stimulation, the least active cells for the longest period. A suitable quantity to give appears to be 100 mc initially and then 50 mc twice weekly, though higher quantities may be possible. Total quantities given by this method have ranged from 300 to as much as 800 mc. It is too soon to decide whether this method has any ultimate advantages, but it seems at present worth while keeping it on trial.
In conclusion, careful technique and consideration of dosage is of particular importance in treatment of thyroid cancer. X-ray therapy needs to be given in high dosage, and megavoltage beam-directed methods, using wedge filters, can be of-value in limiting the treated volume, sparing the spinal cord and posterior half of the neck and upper chest. For hormone treatment sodium Lthyroxine is most generally useful, but the rapidly metabolized sodium L-tri-iodothyronine can be used before and after radioiodine tests and treatment. Radioiodine needs to be given in maximum dosage and decision on its administration should be made after knowledge of its concentration, rather than of crude uptake in tumour, after ablation of normal thyroid.
